What is Augmenta Bioworks?
Augmenta Bioworks is at the forefront of discovering novel therapeutics by harnessing the power of natural human immunity. Their sophisticated technology pinpoints immune receptors and their specific targets, equipping scientists with critical insights for the development of groundbreaking therapies. The company actively engages in collaborations with pharmaceutical giants, emerging biotechnology firms, and leading research institutions. These partnerships aim to bolster vaccine efficacy, identify promising therapeutic antibodies, and accelerate advancements in cell therapies. Augmenta's proprietary DeepGrid platform provides an exhaustive overview of immune system responses, thereby enabling precise modulation of the immune system for effective disease treatment.
How much funding has Augmenta Bioworks raised?
Augmenta Bioworks has raised a total of $338K across 2 funding rounds:
Debt
$150K
Debt
$188K
Debt (2020): $150K with participation from PPP
Debt (2021): $188K led by PPP
What's next for Augmenta Bioworks?
With a substantial late-stage funding context, Augmenta Bioworks is poised for significant scaling and market penetration. The recent strategic investment likely signals a transition towards commercialization or advanced clinical trials for its therapeutic candidates. Future endeavors will probably focus on expanding its collaborative network, further refining its DeepGrid platform, and potentially initiating new research programs targeting unmet medical needs. The company's commitment to leveraging human immunity suggests a long-term vision for revolutionizing disease treatment paradigms.
See full Augmenta Bioworks company page
